Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > Everyone wants to buy cheap!

<< Previous

Bullboard Posts

Next >>

Comment by Chefboy69on Mar 02, 2021 10:44am

71 Views

Post# 32694415

RE:Everyone wants to buy cheap!

remember this B.S post..lol

all someone had to do is wait 24hrs and they could get a 50% discount

LOL...you made your money and are gone now..

what a joke STOCKHOUSE IS

Rezjen wrote:
Creating sell pressure or bashing is the nature of short and people who wants to accumulate at lower price.

A lot of people knows the potential here and the cheaper they can buy the better they are, however they don't know company's strategy, neither do I know. But I can tell you for sure, past 6/7 months update are coming --

partnership, approvals, commercializations are very close if you read between the lines..

long enjoy the ride